

DFIN CASE STUDY

How we helped a biotech company increase collaboration and optimize SEC filing.





CORPORATE SNAPSHOT

Revolution Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients.

Their innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches.



Large Accelerated Filer



As of December 5, 2022

Market cap of~\$2.16B



3 development-stage candidates in clinical trials



Mission Statement
Translating frontier oncology
targets to outsmart cancer™

CHALLENGE

Boost collaboration to save time and drive efficiencies

With a variety of projects, Revolution Medicines was challenged when it came to real-time collaboration with their team and needed to find a way to simplify their financial reporting process.

Revolution Medicines was in search of a tool that allowed for team members to review documents simultaneously and review XBRL tagging. Since they did not have a way to collaborate in real-time, this led to hours of manual review, which was time-consuming.



SOLUTION

New ActiveDisclosure is Faster, Easier to Use, and More Affordable

Revolution Medicines was looking for a solution that would allow their team to collaborate in real-time and to increase efficiency of their financial reporting and SEC filing. New ActiveDisclosure allowed the team to easily collaborate on projects in real-time, simplify iXBRL tagging and streamline processes that were time-consuming in the past.

New ActiveDisclosure also saved the client time and allowed their team to work in Excel and link data for collaboration and reporting.



SECURE COLLABORATION

Multiple contributors can simultaneously develop and review content



EXPERT SUPPORT

24/7/365 support made onboarding seamless



SAVES TIME

Intuitive tools for ease of use and speed to filing

In our opinion, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly,



010-Cover

Josh Duncan Today - 11:16 AM

030-Balance Sheets

Stan Smith Today - 9:55 AM

040-Statements of Operations

Amy Flannery Today - 12:29 AM

Our consolidated finance as of September 30, 202 results of operations for months ended March 3. September 30, 2020, and for 2020. Operating result hree months ended March 3. And September 30, 2020 necessarily indicative of that may be expected for

Do you want to replace this workbook?

Original

Updated

11 Tables

11 Tables

105 Items

105 Items

Assets

ASSECS

Current Assets:

Cash

Accounts receiva

Prepaid expense

Total current ass

T- 01-005 - 01

Building and lan



New AD makes SEC reporting and filing a breeze!

KAUSHIK HANSJEE

Executive Director, Finance and Controller

ASHA INAMDAR


Senior Manager, SEC Reporting





Affordable and Collaborative with Greater Functionality

New ActiveDisclosure is purpose-built with advanced capabilities for fast, accurate reporting. By seamlessly integrating Excel and other data sources, clients that use our secure platform save time, reduce errors, and lower overall costs.





PURPOSE-BUILT

Core tools you need for successful SEC filing and financial reporting, without extra functionalities you'll never use



INTUITIVE

Easy-to-use software with no costly add-ons, hidden costs or annual upsells



EFFICIENT

Streamlines reporting with features like data linking, commenting, Intelligent iXBRL tagging, and more



CONNECTED

Simple integration to your current data sources and tech stack (e.g. Excel/MS Office, ERP)



EXPERT-DRIVEN

24/7/365 support by DFIN financial and SEC reporting experts dedicated to your success



SECURE

Best-in-class, built-in security tools ensure mitigation of data and risk



Get in touch

DFINsolutions.com

DFIN Global Headquarters 35 West Wacker Drive Chicago, Illinois 60601 United States +1 800 823 5304

APAC: +852 2522 3803 EMEA: +44 203 047 6100 LATAM: +55 11 3031 6327